|

Camrelizumab + Nab-paclitaxel + Cisplatin Clinical Trials

2 actively recruiting trials

Also known as: Camrelizumab and chemotherapy

Pipeline

Phase 2: 2

Top Sponsors

  • Sun Yat-sen University1
  • Peking University Cancer Hospital & Institute1

Indications

  • Cancer2
  • Head and Neck Squamous Cell Carcinoma1
  • Esophageal Cancer1

Other2 trials

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
Phase 2
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.